The US FDA Approves Roche’s Xolair for Food Allergies
Read More: Roche
The US FDA Approves AstraZeneca’s Tagrisso, in Combination with Chemotherapy, for Treating EGFRm Advanced NSCLC
Read More: AstraZeneca
Iovance Receives the US FDA’s Accelerated Approval for Amtagvi (lifileucel) as a Treatment for Metastatic Melanoma (MM)
Read More: Iovance
The US FDA’s Accepts Daiichi Sankyo and AstraZeneca’s BLA for Datopotamab Deruxtecan to Treat Non-Small Cell Lung Cancer
Read More: Daiichi Sankyo & AstraZeneca
The European Commission Approves Pfizer’s Velsipity (etrasimod) for the Treatment of Severely Active Ulcerative Colitis
Read More: Pfizer
The US FDA Accepts and Grants Priority Review to argenx’s sBLA of Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Read More: argenx
The US FDA Grants FTD to Certa Therapeutics’ FT011 for the Treatment of Systemic Sclerosis
Read More: Certa Therapeutics
The US FDA Accepts and Grants Priority Review to Merck’s sBLA for Keytruda Plus Chemotherapy to Treat Endometrial Carcinoma
Read More: Merck
The US FDA Accepts and Grants Priority Review to BMS’ sNDA for Krazati & Cetuximab Combination to Treat Colorectal Cancer (CRC)
Read More: BMS
RAPT Therapeutics Reports the US FDA’s Clinical Hold on the Studies Investigating Zelnecirnon
Read More: RAPT Therapeutics
The US FDA Approves Mabwell’s IND Application for 7MW3711 as a Treatment for Solid Tumors
Read More: Mabwell
The US FDA Approves Johnson & Johnson’s sBLA of Tecvayli for Treating Relapsed/Refractory Multiple Myeloma
Read More: Johnson & Johnson
The US FDA Accepts and Grants Priority Review to Sanofi’s sBLA of Dupixent for the Treatment of COPD with Type 2 Inflammation
Read More: Sanofi
The US FDA Grants FTD to Artiva Biotherapeutics’ AlloNK (AB-101) for the Treatment of Lupus Nephritis
Read More: Artiva Biotherapeutics
The CHMP Grants Positive Opinion toCSL Vifor and Travere Therapeutics’ Sparsentan for the Treatment of IgA Nephropathy
Read More: Artiva Biotherapeutics
Almirall and Novo Nordisk Collaborate to Develop NN-8828 for Treating Dermatological Diseases
Read More: Almirall & Novo Nordisk
Immune-Onc Therapeutics and Roche Partner to Assess IO-108 for the Treatment of Advanced Hepatocellular Carcinoma
Read More: Immune-Onc Therapeutics and Roche
Biocytogen and Gilead have Signed a Multi-Target Antibody Collaboration Agreement to Select and Develop Therapeutic Targets for the Treatment of Multiple Disease
Read More: Biocytogen & Gilead
Mainz Biomed Collaborates with TomaLab for Enhancing the Diagnosis of Colorectal Cancer Using ColoAlert
Read More: Mainz Biomed & TomaLab
Immunocore and BMS Collaborate for the Development of IMC-F106C in the P-III Trial for the Treatment of Melanoma
Read More: Immunocore & BMS
AbbVie and Tentarix Biotherapeutics Collaborate to Develop Biologics for Oncology and Immunology
Read More: AbbVie & Tentarix
Boehringer Ingelheim Collaborates with Sleip AI to Utilize AI-technology for Detecting Lameness in Horse
Read More: Boehringer Ingelheim & Sleip AI
Ono Pharmaceutical and InveniAI Sign a Research Collaboration Agreement for the Identification of Novel Therapeutic Targets Using AI and ML
Read More: Ono Pharmaceutical & InveniAI
Innovent Highlights the P-III (RESTORE-1) Trial Results of IBI311 to Treat Thyroid Eye Disease (TED)
Read More: Innovent
ViiV Healthcare (GSK & Pfizer’s Global Specialist HIV Company) Highlights P-III (LATITUDE) Trial Results of Cabenuva (cabotegravir + rilpivirine) for HIV
Read More: ViiV Healthcare
Aleta Biotherapeutics Doses First Patient with ALETA-001 in P-I/II Trial for the Treatment of R/R B-Cell Malignancies
Read More: Aleta Biotherapeutics
CymaBay Publishes P-III Results for Seladelpar as a Treatment of Primary Biliary Cholangitis in the New England Journal of Medicine
Read More: CymaBay
SynAct Pharma Highlights Further Analysis from the P-IIb (EXPAND) Study Supporting the Development of Resomelagonin for Rheumatoid Arthritis
Read More: SynAct Pharma
Mabwell Publishes the P-III Study Results of MW032 (Biosimilar, Denosumab) for Solid Tumors in JAMA Oncology
Read More: Mabwell
